Opportunities for improving therapy development in ALS

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 15, Issue 3-4, 2014, Pages 169-173

  Bruijn, Lucie ^a   Cudkowicz, Merit ^b  

^a ALS Association   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Amyotrophic lateral sclerosis; Biomarkers; Clinical trials; Therapy

Indexed keywords

BIOLOGICAL MARKER; GLUTAMATE TRANSPORTER; LITHIUM; MINOCYCLINE; PLACEBO; UBIDECARENONE;

AMYOTROPHIC LATERAL SCLEROSIS; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE FACILITY; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PATIENT EDUCATION; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; REGISTER; REVIEW; STUDY DESIGN; SURVIVAL; TREATMENT OUTCOME; CLASSIFICATION; METHODOLOGY; PROCEDURES;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; RESEARCH DESIGN;

EID: 84901503229     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2013.872662     Document Type: Review

References (17)

1. Groeneveld GJ, Veldink JH, van der Tweel I, Kalmijn S, Beijer C, de Visser M, et al. A placobo-controlled doubleblind randomized trial in patients with amyotrophic lateral sclerosis with creatine monohydrate: A randomized sequential trial. Ann Neurol. 2003;53:437-45
2. Aggarwal SP, Zinman L, Simpson E, McKinley J, Jackson KE, Pinto H, et al .; Northeast and Canadian Amyotrophic Lateral Sclerosis consortia. Safety and effi cacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: A randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:481-8
3. Verstraete E, Veldink JH, Huisman MH, Draak T, Uijtendaal EV, van der Kooi AJ, et al. Lithium lacks effect on survival in amyotrophic lateral sclerosis: A phase IIb randomized sequential trial. J Neurol Neurosurg Psychiatry. 2012;83:557-64
4. UKMND-LiCALS Study Group, Morrison KE, Dhariwal S, Hornabrook R, Savage L, Burn DJ, et al. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): A phase III multicentre, randomized, double-blind, placebocontrolled trial. Lancet Neurology. 2013;12:339-45
5. Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, et al .; QALS Study Group. Phase II trial of CoQ10 for ALS fi nds insuffi cient evidence to justify phase III. Ann Neurol. 2009;66:235-44
6. Coffey C S. Adaptive Design Across Stages of Therapeutic Development. In: Ravina B, Cummings J, McDermott M, Poole RM. Clinical Trials in Neurology: Design, Conduct, and Analysis. Cambridge: Cambridge University Press;2012. pp 91-100
7. Maca J, Bhattacharya S, Dragalin V, Gallo P, Krams M. Adaptive seamless phase II/III designs: Background operational aspects and examples. Drug Inf J. 2006;40:463-73. (Pubitemid 44721124
8. Berry JD, Shefner JM, Conwit R, Schoenfeld D, Keroack M, Felsenstein D, et al ., Northeast ALS Consortium. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One. 2013;8:e61177
9. NeuroNEXT.org http://www.neuronext.org/ Viewed online 23 July 2013
10. Prize4Life Announces $ 50,000 ALS Prediction Prize Winners. http://www.prize4life.org/page/news/10194. Viewed online 23 July 2013
11. Wang SJ, Hung H MJ, O ' N eill R T. A daptive patient enrichment designs in therapeutic trials. Biometrical J. 2009;51:358-74
12. Butovsky O, Siddiqui S, Gabriely G, Lanser AJ, Dake B, Murugaiyan G, et al. Modulating infl ammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest. 2012;122:3063-87
13. Gooch CL, Shefner JM. A LS surrogate markers. M UNE. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5 (Suppl 1):104-7
14. Neuwirth C, Nandedkar S, S t ål berg E, Barkhaus PE, Carvalho MD, Furtula J, et al. Motor Unit Number Index (MUNIX): Reference values of fi ve different muscles in healthy subjects from a multicentre study. Clin Neurophysiol. 2011;122:1895-8
15. R utkove SB, Zhang H, Schoenfeld DA, Raynor EM, Shefner JM, Cudkowicz ME, et al. Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trials. Clin Neurophysiol. 2007;118:2413-8
16. Morgan P, van der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, et al. Can the fl ow of medicines be improved?. Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov Today. 2012;17:419-24
17. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Effi cacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomized trial. Lancet Neurol. 2007;6:1045-53. (Pubitemid 350116691.